BIIB241129P230000
- 0.00
- 0.000.00%
Biogen Newsroom
RBC Capital Sticks to Its Buy Rating for Biogen (BIIB)
Eisai, Biogen Launch Leqembi in South Korea
Wednesday Ends With Index Decline | Wall Street Today
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024?
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
"LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Biogen Put Volume Heavy and Directionally Bearish
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
Are Biogen Inc.'s (NASDAQ:BIIB) Mixed Financials Driving The Negative Sentiment?
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250
Jefferies Remains a Buy on Biogen (BIIB)
S&P 500, Dow Hit Records Right After Open | Live Stock
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Market Climbs, Bitcoin Close to $100k | Live Stock
Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock
Biogen Price Target Lowered to $207 From $251 at Mizuho